NUREXONE BIOLOGIC INC (NRXBF)
- Previous Close
0.5318 - Open
0.5400 - Bid 0.5313 x 500000
- Ask 0.5429 x 300000
- Day's Range
0.5400 - 0.5600 - 52 Week Range
0.3556 - 0.6075 - Volume
35,500 - Avg. Volume
10,112 - Market Cap (intraday)
44.308M - Beta (5Y Monthly) -0.03
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.50
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat traumatic brain injuries and other neurological conditions. Its technology includes ExoPTEN for the treatment of acute spinal cord injury and glaucoma; and Exosomes as a drug delivery system for regeneration and healing of specific tissues. The company was founded in 2020 and is based in Toronto, Canada.
nurexone.comRecent News: NRXBF
View MorePerformance Overview: NRXBF
Trailing total returns as of 6/10/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NRXBF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NRXBF
View MoreValuation Measures
Market Cap
43.87M
Enterprise Value
43.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
33.67
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-115.19%
Return on Equity (ttm)
-234.44%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.8M
Diluted EPS (ttm)
-0.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
588k
Total Debt/Equity (mrq)
2.36%
Levered Free Cash Flow (ttm)
-2.93M